Why Rani Therapeutics Holdings, Inc.’s (RANI) Stock Is Down 5.40%
As of Tuesday, November 10, Rani Therapeutics Holdings, Inc.’s RANI share price has dipped by 5.40%, which has investors questioning if this is right time to buy.Rosalio Madrigal
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Rosalio Madrigal
Tudor Pop
Jenna Brashear
Jenna Brashear
Jenna Brashear
| Share Statistics | RANI | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $60.7 | $447.9 | 18% |
|
| Shares Out (Mil) | 199.0 | 46.7 | 75% |
|
| Institutional Ownership | 87.0% | 80.9% | 55% |
|
| Float (Mil) | 82.3 | 46.8 | 56% |
|
| Beta | na | 0.74 | na |
|
| Avg Daily Volume (000s) | 499 | 342 | 57% |
|
| Price Change (52-week) |
(75.2%) | 54.7% | 10% |
|
| Growth | RANI | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 26.2% | 6.1% | 87% |
|
| Net Income (5yr) | na | (1.6%) | na |
|
| EPS (5yr) | na | 15.0% | na |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (28.9%) | (15.1%) | 21% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 4 | 4 | |
| Current EPS | ($0.043) | ($0.168) | ($0.190) | |
| Month Ago EPS | ($0.050) | ($0.173) | ($0.190) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.047) | ($0.173) | ($0.193) | |
| Year/Year Chg | 7.5% | (62.6%) | (65.0%) | |
| Financials | RANI | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $7 | $303 | 7% |
|
| Net Income (TTM) (Mil) | ($33) | ($10) | 20% |
|
| EPS (TTM) | ($0.189) | ($0.600) | 33% |
|
| Operating Cash Flow (TTM) (Mil) | ($23) | ($7) | 14% |
|
| Net Cash Flow (TTM) (Mil) | ($1) | $1 | 42% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $6 | 20% |
|
| Enterprise Value (Q1) (Mil) | $32 | $408 | 14% |
|
| Valuation | RANI | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.81 | 2.19 | 51% |
|
| P/E | na | 22.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | RANI | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 69.5% | 96% |
|
| Net Margin | (493.0%) | 3.9% | 2% |
|
| ROA | (103.6%) | (22.7%) | 5% |
|
| ROE | (248.6%) | (25.0%) | 3% |
|
| Liabilities to Assets | 21.3% | 31.8% | 14% |
|
| F-Score | 3 | 3 | 18% |
|
Rani Therapeutics Holdings, Inc. did not pass any screens on 11/13/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors